Latest Content

Novartis investors intensify pressure on the company's M&A strategy after a string of trial failures, Michelle Carnahan argues health care needs an orchestration layer rather than more point solutions, and Nacho Quinones and Aisling O'Loughlin make the case for synthetic advisory boards in biopharma decision-making.

The advantages of synthetic advisory boards in stress-testing hypotheses and iterating across a greater scope of scenarios than live boards allow.

Novartis shareholders share deepened trust issues around the company's dealmaking strategy.

As leaders, we must evaluate solutions to fragmentation by asking the right questions.

Ten life sciences board directors on AI's three hardest questions: developing the next generation of talent, accountability for speed, and board fluency.

Dr. Elena Christofides on why treatment failure in diabetes should trigger a cortisol screen — not an assumption of non-adherence.

Artisan Partners' David Samra calls for a board shake-up at Novartis after costly deal failures, Kura Oncology spins out Caspian Therapeutics to pursue menin inhibition for diabetes, and Ira Studin examines how payers are redefining unmet need for orphan products.

Why clinical out-of-home marketing has finally become responsive after decades of running static, scheduled messages.

A “maturity curve” can help organizations move engagement beyond performative gestures to a strategic asset.

Unmet need is likely a new battlefield impacting prior authorization.

Artisan Partners' David Samra is publicly calling for Novartis to overhaul its board and compensation structure following back-to-back trial failures.

Dr. Elena Christofides on why the overnight dexamethasone suppression test is the only cortisol screen that actually identifies HPA dysfunction.

Kura Oncology spins out Caspian Therapeutics to apply its menin inhibitor expertise to diabetes — with Eli Lilly validating the science.